High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity

Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here, we isolated a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leukemia
Auteurs principaux: Lynn, Rachel C, Feng, Yang, Schutsky, Keith, Poussin, Mathilde, Kalota, Anna, Dimitrov, Dimiter S, Powell, Daniel J
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4889499/
https://ncbi.nlm.nih.gov/pubmed/26898190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.35
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires